JUNO Description — Juno Therapeutics Inc
Juno Therapeutics is a biopharmaceutical company focused on the treatment of cancer. Co. is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and high-affinity T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Co.'s CAR and TCR technologies alter T cells ex vivo, so that the T cells can recognize specific proteins on the surface or inside cancer cells or other diseased cells in order to kill those diseased cells. Co.'s product candidates, JCAR017, JCAR014, and JCAR015 utilize CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas.